General

Dr. Huacheng Luo is a professor of the Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences. He engaged in scientific research at University of Florida and the Pennsylvania State University in United States. Dr. Luo lab research aims are focused on identifying how the epigenetic landscape profiling is capable of influencing the initiation and progression of cancer and exploring new technologies for cancer treatment, including: 1). Clarifying the epigenetics mechanism of functional nucleic acid targeting m6A modifying complex in carcinogenesis; 2 ). Uncovering the molecular mechanism of long non-coding RNA mediating three-dimensional genome organization in normal hematopoiesis and malignant leukemogenesis; 3). Investigating the functional mechanism of aptamer targeting SOST(sclerostin) in malignant tumor therapeutics. Dr. Luo’s studies have been published in the international peer-reviewed journals, including Leukemia (2023), Molecular Cell (2022, Cover article), Cancer Cell (2019, Cover article), Blood (2018, Cover article), Science Advances (2020), Nature Communications (2021), Oncogene (2022), Advanced Science (2021) etc. His studies were supported by the Leukemia Research Foundation (LRF) and NCI in United States. Currently, his research projects are funded by the National Natural Science Foundation of China and the Zhejiang Provincial Natural Science Foundation of China.



Research Areas

Dr. Luo lab research aims are focused on identifying how the epigenetic landscape profiling is capable of influencing the initiation and progression of cancer and exploring new mechanism(s) for cancer therapeutics, including: 1). Clarifying the epigenetics mechanism of functional nucleic acid targeting m6A modifying complex in carcinogenesis; 2 ). Uncovering the molecular mechanism of long non-coding RNA mediating three-dimensional genome organization in normal hematopoiesis and malignant leukemogenesis; 3). Investigating the functional mechanism of aptamer targeting SOST(sclerostin) in malignant tumor therapeutics.

Publications

1.    Qian Lai#, Karina Hamamoto#, Huacheng Luo#(Co-first author), Julia Lesperance, Jie Zha, Yi Qiu, Olga Guryanova, Suming Huang, and Bing Xu. NPM1 mutation reprograms leukemic transcription network via reshaping TAD topology. Leukemia, 2023, Aug;37(8):1732-173. (IF: 12.883)

2.   Huacheng Luo, Ganqian Zhu, Melanie Eshelman, Xiaoyan Ma, Qian Lai, Nicholas Cesari, Shi Chen, Christopher Cogle, Ruben Mesa, Sinisa Dovat, Chi Wai Eric So, Feng-Chun Yang, Yi Qiu, Mingjiang Xu, and Suming Huang. HOTTIP dependent R-loop formation regulates CTCF boundary and TAD integrity in acute myeloid leukemia. Molecular Cell. 2022, 82(4): 833–851. (IF: 19.328,  Cover story)

3.    Ajeet Singh*, #, Huacheng Luo*,#, Meghana Matur, Melanie Eshelman, Karina Hamamoto, Arati Sharma, Julia Lesperance, Suming Huang. A coordinated function of lncRNA HOTTIP and miRNA-196b underpinning leukemogenesis by targeting Fas signaling. Oncogene. 2022, 41, 718–731. (#Co-first and *Co-corresponding author,  IF: 9.867)

4.    Lei Zhang, Huacheng Luo# (Co-first author), Hong-Min Ni, Shanhui Liu, Hongyun Xing, Jun Zhang, Mark Sellin, SJ Peter Breslin, Wei Wei, Mitchell F Denning, William Small Jr, Wen-Xing Ding, Suming Huang, Jiwang Zhang. Ripk3 signaling regulates HSCs during stress and represses radiation-induced leukemia in mice. Stem Cell Reports. 2022 Apr 30; S2213-6711(22)00198-9. (IF: 7.765)

5.    Ganqian Zhu#, Huacheng Luo# (Co-first author), Yang Feng, Olga A. Guryanova, Jianfeng Xu, Shi Chen, Qian Lai, Arati Sharma, Bing Xu, Zhigang Zhao, Ru Feng, Hongyu Ni, David Claxton, Ying Guo, Ruben A. Mesa, Yi Qiu, Feng-Chun Yang, Wei Li, Stephen D. Nimer, Suming Huang and Mingjiang Xu. HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia. Nature Communications. 2021, 12(1):1956. (IF: 17.694). 

6.    Yiju Wei#, Huacheng Luo# (Co-first author), Patricia P. Yee, Lijun Zhang, Zhijun Liu, Haiyan Zheng, Lei Zhang, Benjamin Anderson, Suming Huang and Wei Li. Paraspeckle Protein NONO Promotes TAZ Phase Separation in the Nucleus to Drive the Oncogenic Transcriptional Program. Advanced Science. 2021, 8(24):e2102653; PubMed PMID: 34716691. (IF: 17.521)

7.    Huacheng Luo, Qin Yu, Yang Liu, Ming Tang, Mingwei Liang, Dingpeng Zhang, Tsan Sam Xiao, Lizi Wu, Ming Tan, Yijun Ruan, Jörg Bungert, Jianrong Lu. LATS kinase-mediated CTCF phosphorylation and selective loss of genomic binding. Science Advances. (2020). Vol. 6, no. 8, eaaw4651. (IF: 14.957). 

8.    Huacheng Luo, Ganqian Zhu, Jianfeng Xu, Qian Lai, Bowen Yan, Ying Guo, Tsz Kan Fung, Bernd B. Zeisig, Ya Cui, Jie Zha, Christopher Cogle, Fei Wang, Bing Xu, Feng-Chun Yang, Wei Li, Chi Wai Eric So, Yi Qiu, Mingjiang Xu, and Suming Huang. HOTTIP lncRNA promotes hematopoietic stem cell self-renewal leading to AML-like disease in mice. Cancer Cell. (2019). 36(6):645-659.e8. (IF: 50.3,  Cover story)

9.    Huacheng Luo*, Amin Sobh, Christopher Vulpe, Edmond Brewer, Sinisa Dovat, Yi Qiu and Suming Huang*. HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries. Journal of Visualized Experiments. (145), e59382, doi:10.3791/59382 (2019). (IF: 1.424, *Co-corresponding author)

10. Huacheng Luo, Fei Wang, Jie Zha, Haoli Li, Bowen Yan, Qinghua Du, Fengchun Yang, Amin Sobh, Christopher Vulpe, Leylah Drusbosky, Christopher Cogle, Iouri Chepelev , Bing Xu, Stephen Nimer, Jonathan Licht, Yi Qiu,Baoan Chen, Mingjiang Xu, and Suming Huang. CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia. Blood. (2018), 132(8):837-848. (IF: 25.476) (Cover story).

11. Huacheng Luo, Anitha K Shenoy, Xuehui Li, Yue Jin, Lihua Jin, Qingsong Cai, Ming Tang, David Reisman, Lizi Wu, Yi Qiu, Yali Dou, Robert Casero, Yang Liu, Jianrong Lu. MOF Acetylates the Histone Demethylase LSD1 to Suppress Epithelial-to-Mesenchymal Transition. (2016). Cell Reports. 15(12), 2665–2678. (IF: 9.995) 


Conferences

1.        Huacheng Luo et al. The Role of Hottip Lncrna m6A Modification in AML Genome Organization and Leukemogenesis. The 64th American Society of Hematology (ASH) Annual Meeting and Exposition, December 10-13, 2022, New Orleans, LA. (Oral presentation).

2.        Huacheng Luo et al.  Hottip-Mediated R-Loops Regulate CTCF TAD Boundary to Control WNT/b-Catenin Pathway in AML Genome. The 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8th, 2020, San Diego, CA. (Oral presentation).

3.        Huacheng Luo et al. HOTTIP lncRNA reinforces CTCF defined chromatin boundaries and drives Wnt target gene expression in AML leukemogenesis.  The 61st American Society of Hematology (ASH) Annual Meeting and Exposition,  December 7-10, 2019, Orlando, FL. (Oral presentation).

4.        Huacheng Luo et al. Activation of HOTTIP lncRNA perturbs HSC function leading to AML-like disease in mice. The 60th American Society of Hematology (ASH) Annual Meeting and Exposition,December 1-4, 2018, San Diego, CA.  (Poster presentation).

5.        Huacheng Luo et al. Disruption of CTCF Boundary Remodels Chromatin Domain and Reprograms HOX Gene Transcription in Acute Myeloid Leukemia. The 59th American Society of Hematology (ASH) Annual Meeting and Exposition, December 9-12, 2017, Atlanta, GA. (BEST Oral presentation).